Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A (688212) - Net Assets
Based on the latest financial reports, Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A (688212) has net assets worth CN¥1.28 Billion CNY (≈ $186.67 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.86 Billion ≈ $271.68 Million USD) and total liabilities (CN¥580.99 Million ≈ $85.02 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 688212 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.28 Billion |
| % of Total Assets | 68.71% |
| Annual Growth Rate | 21.5% |
| 5-Year Change | 153.39% |
| 10-Year Change | N/A |
| Growth Volatility | 51.12 |
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A - Net Assets Trend (2019–2024)
This chart illustrates how Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. See Shanghai Aohua Photoelectricity Endoscop (688212) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A (2019–2024)
The table below shows the annual net assets of Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A from 2019 to 2024. For live valuation and market cap data, see Shanghai Aohua Photoelectricity Endoscop (688212) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.38 Billion ≈ $202.01 Million |
-1.05% |
| 2023-12-31 | CN¥1.40 Billion ≈ $204.16 Million |
+8.86% |
| 2022-12-31 | CN¥1.28 Billion ≈ $187.54 Million |
+1.81% |
| 2021-12-31 | CN¥1.26 Billion ≈ $184.21 Million |
+131.07% |
| 2020-12-31 | CN¥544.80 Million ≈ $79.72 Million |
+4.54% |
| 2019-12-31 | CN¥521.16 Million ≈ $76.26 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1366.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥140.23 Million | 10.27% |
| Other Components | CN¥1.23 Billion | 89.73% |
| Total Equity | CN¥1.37 Billion | 100.00% |
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Atom Hoteles Socimi
MC:YATO
|
$548.78 Million |
|
Zhejiang Yatai Pharmaceutical Co Ltd
SHE:002370
|
$548.85 Million |
|
Stadio Holdings Ltd
JSE:SDO
|
$548.96 Million |
|
Benakat Petroleum Energy
JK:BIPI
|
$549.00 Million |
|
Shanghai HIUV New Materials Co Ltd
SHG:688680
|
$548.37 Million |
|
Energisa Mato Grosso - Distribuidora de Energia S/A
SA:ENMT3
|
$548.20 Million |
|
Flying Technology Co Ltd
SHG:603488
|
$548.19 Million |
|
CHC Resources Corp
TW:9930
|
$548.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,379,991,271 to 1,366,055,677, a change of -13,935,594 (-1.0%).
- Net income of 21,012,249 contributed positively to equity growth.
- Dividend payments of 41,596,014 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥21.01 Million | +1.54% |
| Dividends Paid | CN¥41.60 Million | -3.04% |
| Other Changes | CN¥6.65 Million | +0.49% |
| Total Change | CN¥- | -1.01% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.74x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.44x to 2.74x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥5.12 | CN¥27.83 | x |
| 2020-12-31 | CN¥5.34 | CN¥27.83 | x |
| 2021-12-31 | CN¥9.36 | CN¥27.83 | x |
| 2022-12-31 | CN¥9.51 | CN¥27.83 | x |
| 2023-12-31 | CN¥10.30 | CN¥27.83 | x |
| 2024-12-31 | CN¥10.15 | CN¥27.83 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.80%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 1.28x
- Recent ROE (1.54%) is below the historical average (4.30%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 10.34% | 17.77% | 0.50x | 1.17x | CN¥1.73 Million |
| 2020 | 3.46% | 7.03% | 0.42x | 1.18x | CN¥-34.92 Million |
| 2021 | 4.57% | 16.43% | 0.26x | 1.08x | CN¥-67.82 Million |
| 2022 | 1.71% | 4.87% | 0.30x | 1.15x | CN¥-105.11 Million |
| 2023 | 4.19% | 8.53% | 0.43x | 1.16x | CN¥-80.14 Million |
| 2024 | 1.54% | 2.80% | 0.43x | 1.28x | CN¥-115.59 Million |
Industry Comparison
This section compares Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $3,442,122,104
- Average return on equity (ROE) among peers: 12.05%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A (688212) | CN¥1.28 Billion | 10.34% | 0.46x | $548.41 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $4.98 Billion | -4.70% | 0.37x | $371.06 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $2.13 Billion | 17.09% | 0.37x | $3.63 Billion |
| Double Medical Technology Inc (002901) | $3.11 Billion | 2.98% | 0.27x | $2.56 Billion |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $6.77 Billion | 62.15% | 0.36x | $506.97 Million |
| Lepu Medical Tech Beijing (300003) | $10.54 Billion | 17.10% | 0.73x | $3.19 Billion |
| INKON Life Technology Co Ltd (300143) | $343.97 Million | 0.00% | 1.34x | $764.39 Million |
| Edan Instruments Inc (300206) | $1.25 Billion | 3.50% | 0.14x | $1.15 Billion |
| Guangdong Biolight Meditech Co Ltd (300246) | $1.39 Billion | -4.69% | 0.82x | $735.30 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $761.02 Million | 12.92% | 0.49x | $467.29 Million |
| Sinocare Inc (300298) | $3.14 Billion | 14.20% | 0.47x | $1.17 Billion |
About Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
Shanghai Aohua Photoelectricity Endoscope Co., Ltd. engages in the research and development, manufacture, and sale of electronic endoscope equipment and endoscopic diagnosis and treatment consumables in China and internationally. It offers electronic digestive endoscopes, otolaryngoscopes, bronchoscopes, and endoscopic diagnostic and treatment consumables for use in respiratory medicine, general … Read more